Linked Life Data

19299439

Source:http://linkedlifedata.com/resource/pubmed/id/19299439

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:19299439rdf:typepubmed:Citationlld:pubmed
pubmed-article:19299439lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:19299439lifeskim:mentionsumls-concept:C0332307lld:lifeskim
pubmed-article:19299439lifeskim:mentionsumls-concept:C0015980lld:lifeskim
pubmed-article:19299439lifeskim:mentionsumls-concept:C0475463lld:lifeskim
pubmed-article:19299439lifeskim:mentionsumls-concept:C0751967lld:lifeskim
pubmed-article:19299439lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:19299439lifeskim:mentionsumls-concept:C0205210lld:lifeskim
pubmed-article:19299439lifeskim:mentionsumls-concept:C0332291lld:lifeskim
pubmed-article:19299439pubmed:issue5lld:pubmed
pubmed-article:19299439pubmed:dateCreated2009-4-24lld:pubmed
pubmed-article:19299439pubmed:abstractTextTo establish whether the clinical effect of neutralizing antibodies (NAbs) against interferon-beta (IFN beta) depends on the type of IFNbeta (1a or 1b) used for treatment of patients with relapsing-remitting multiple sclerosis (MS).lld:pubmed
pubmed-article:19299439pubmed:languageenglld:pubmed
pubmed-article:19299439pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19299439pubmed:citationSubsetIMlld:pubmed
pubmed-article:19299439pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19299439pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19299439pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19299439pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19299439pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19299439pubmed:statusMEDLINElld:pubmed
pubmed-article:19299439pubmed:monthMaylld:pubmed
pubmed-article:19299439pubmed:issn1352-4585lld:pubmed
pubmed-article:19299439pubmed:authorpubmed-author:BendtzenKKlld:pubmed
pubmed-article:19299439pubmed:authorpubmed-author:Koch-Henrikse...lld:pubmed
pubmed-article:19299439pubmed:authorpubmed-author:SorensenP SPSlld:pubmed
pubmed-article:19299439pubmed:authorpubmed-author:FlachsE MEMlld:pubmed
pubmed-article:19299439pubmed:issnTypePrintlld:pubmed
pubmed-article:19299439pubmed:volume15lld:pubmed
pubmed-article:19299439pubmed:ownerNLMlld:pubmed
pubmed-article:19299439pubmed:authorsCompleteYlld:pubmed
pubmed-article:19299439pubmed:pagination601-5lld:pubmed
pubmed-article:19299439pubmed:meshHeadingpubmed-meshheading:19299439...lld:pubmed
pubmed-article:19299439pubmed:meshHeadingpubmed-meshheading:19299439...lld:pubmed
pubmed-article:19299439pubmed:meshHeadingpubmed-meshheading:19299439...lld:pubmed
pubmed-article:19299439pubmed:meshHeadingpubmed-meshheading:19299439...lld:pubmed
pubmed-article:19299439pubmed:meshHeadingpubmed-meshheading:19299439...lld:pubmed
pubmed-article:19299439pubmed:meshHeadingpubmed-meshheading:19299439...lld:pubmed
pubmed-article:19299439pubmed:meshHeadingpubmed-meshheading:19299439...lld:pubmed
pubmed-article:19299439pubmed:meshHeadingpubmed-meshheading:19299439...lld:pubmed
pubmed-article:19299439pubmed:meshHeadingpubmed-meshheading:19299439...lld:pubmed
pubmed-article:19299439pubmed:meshHeadingpubmed-meshheading:19299439...lld:pubmed
pubmed-article:19299439pubmed:meshHeadingpubmed-meshheading:19299439...lld:pubmed
pubmed-article:19299439pubmed:meshHeadingpubmed-meshheading:19299439...lld:pubmed
pubmed-article:19299439pubmed:meshHeadingpubmed-meshheading:19299439...lld:pubmed
pubmed-article:19299439pubmed:meshHeadingpubmed-meshheading:19299439...lld:pubmed
pubmed-article:19299439pubmed:meshHeadingpubmed-meshheading:19299439...lld:pubmed
pubmed-article:19299439pubmed:meshHeadingpubmed-meshheading:19299439...lld:pubmed
pubmed-article:19299439pubmed:meshHeadingpubmed-meshheading:19299439...lld:pubmed
pubmed-article:19299439pubmed:year2009lld:pubmed
pubmed-article:19299439pubmed:articleTitleThe clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis.lld:pubmed
pubmed-article:19299439pubmed:affiliationDepartment of Neurology, Aarhus University Hospital in Aalborg, Denmark and The Danish MS Treatment Register, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark. koch-henriksen@stofanet.dklld:pubmed
pubmed-article:19299439pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:19299439pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:19299439pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed